Trial Profile
Phase II Feasibility study of Weekly Amrubicin in Patients with Previously Treated Non-small Cell Lung Cancer
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 24 Jan 2013
Price :
$35
*
At a glance
- Drugs Amrubicin (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 16 Nov 2012 New trial record